Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Adenocarcinoma of the lung classification
Introduction
Overview
Overview
Adenocarcinoma of the lung may be classified according to WHO into many sub-types. Adenocarcinoma of the lung may be classified according to IASLC/ATS/ERS into pre-invasive lesions, atypical adenomatous hyperplasia, adenocarcinoma in situ, minimally invasive adenocarcinoma, invasive adenocarcinoma, and variants of invasive adenocarcinoma.
Classification
Classification
- Adenocarcinomas are highly heterogeneous tumors.
- Several major histological sub-types are currently recognized by the WHO and IASLC/ATS/ERS classification systems.[1][2][3]
- The IASLC/ATS/ERS lung adenocarcinoma histological classification system was proposed in 2011.[4]
- According to this new classification, tumor size ≤ 3 cm with pure lepidic pattern, but without lymphatic, vascular, and pleural invasion or tumor necrosis, was defined as adenocarcinoma in situ (AIS).
- If tumor size ≤ 3 cm with a lepidic predominant pattern and contained ≤ 5 mm stromal invasion, it was defined as minimally invasive adenocarcinoma (MIA).
- If tumor had > 5 mm stromal invasion, it was defined as an invasive adenocarcinoma.
- The WHO histological classification of adenocarcinoma is following:[5][6]
| WHO Classification of Lung Tumors | |
|---|---|
| Histological type | Subtype |
| Epithelial Tumors | |
| Adenocarcinoma |
|
References
References
- ↑ Van Schil, P. E.; Asamura, H; Rusch, V. W.; Mitsudomi, T; Tsuboi, M; Brambilla, E; Travis, W. D. (2012). “Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification”. European Respiratory Journal. 39 (2): 478–86. doi:10.1183/09031936.00027511. PMID 21828029.
- ↑ Travis, W. D.; Brambilla, E; Van Schil, P; Scagliotti, G. V.; Huber, R. M.; Sculier, J. P.; Vansteenkiste, J; Nicholson, A. G. (2011). “Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification”. European Respiratory Journal. 38 (2): 239–43. doi:10.1183/09031936.00026711. PMID 21804158.
- ↑ Vazquez, M; Carter, D; Brambilla, E; Gazdar, A; Noguchi, M; Travis, W. D.; Huang, Y; Zhang, L; Yip, R; Yankelevitz, D. F.; Henschke, C. I.; International Early Lung Cancer Action Program Investigators (2009). “Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: Histopathologic features and their prognostic implications”. Lung Cancer. 64 (2): 148–54. doi:10.1016/j.lungcan.2008.08.009. PMC 2849638. PMID 18951650.
- ↑ . doi:10.3978/j.issn.2072-1439.2014.09.13. Missing or empty
|title=(help) - ↑ Travis, William (2004). Pathology and genetics of tumours of the lung, pleura, thymus, and heart. Lyon: IARC Press. ISBN 9283224183.
- ↑ “www.jto.org”.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Trusha Tank, M.D.[2]Shanshan Cen, M.D. [3] Sudarshana Datta, MD [4]